Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH), the world leader in the development of a new class of small molecule compounds based on endogenous adrenal steroid hormones, today presented new findings regarding the potential mechanism of action of APOPTONE™ (HE3235), the Company's drug candidate in development for the treatment of prostate cancer.

Filed under: Colitis, Main Content